Last updated 2026-07-27
- Went public on NASDAQ (ORGS), Aug 2011
- Raised $12.8M grant, Jan 2017
- Raised $10M debt round led by Accredited investors, Dec 2015
Total raised
$28.2M
Last: Debt Financing 2025-01
Stage
Public
Founded
2008
Headcount
77
HQ
Germantown, United States
Sector
Health Tech & Life Sciences
About
Orgenesis is a global biotech company committed to unlocking the potential of cell and gene therapies (CGTs) in an affordable and accessible format. The company focuses on autologous therapies, with processes and systems developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment at the point of care (POCare). Orgenesis aims to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production.
Funding history · 5 rounds · $28.2M total
2018-02
Follow-on PO
Undisclosed
2017-01
Grant
$12.8M
2015-12
Debt Financing
$10.0M
★ Accredited investors
2014-10
Grant
$2.4M
2013-11
Undisclosed Round
$3.0M
★ Kodiak Capital Group
Headcount over time
From 6 (2018-09) to 39 (2026-03) · +33 (+550%) · 55 points · source: Finder history + radar grounding
Q&A
- What was Orgenesis's most recent funding round?
- In January 2025, Orgenesis secured $5,000,000 in Debt Financing from Williamsburg Venture Holdings, LLC.
- What was the amount of the Convertible Debt round Orgenesis received in 2025?
- In 2025, Orgenesis received $1,000,000 in Convertible Debt from Alpha Prosperity Fund SPC.
- What was the most recent Public Offering for Orgenesis?
- In 2024, Orgenesis had a Public Offering with Nathan Low & 5 more investors.
- What was the amount of the Public Offering Orgenesis completed in October 2023?
- In October 2023, Orgenesis completed a Public Offering of $5,000,000 with Metalmark Capital Partners.
- What was the amount of the Convertible Debt round Orgenesis received in November 2022?
- In November 2022, Orgenesis received $50,000,000 in Convertible Debt from Yehuda Nir and Metalmark Capital.
- When did Orgenesis commence trading on the OTCQX Best Market?
- Orgenesis commenced trading on the OTCQX® Best Market on October 21, 2024.
- What was a significant acquisition made by Orgenesis in early 2024?
- In January 2024, Orgenesis acquired control of Octomera, aiming to progress its decentralized immuno-oncology portfolio to the clinic.
- What strategic partnership did Orgenesis announce in August 2024?
- In August 2024, Orgenesis announced a strategic partnership with Harley Street Healthcare Group to launch a global longevity & wellness initiative.
- What was the outcome of the real-world study for Orgenesis's ORG-101 CAR-T therapy announced in August 2024?
- In August 2024, Orgenesis announced positive results from a real-world study of ORG-101 CAR-T therapy in patients with CD19+ Acute Lymphoblastic Leukemia.
Team · 1
Sarah Ferber
Founder · Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesHealthcareLaboratoriesProvidersLife SciencesPharmaceuticalsBiotechnology
Business model
B2B
Highlights
1 Patents
Tags
therapeuticscell-therapydiabetesmedical-technologiesbiotechnologylaboratoriespharma-companiesimmunotherapyhospitalsacademiaoncologyregenerative-medicinetreatmentsbioconvergence
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | orgenesis.com |
|---|---|
| linkedin.com/company/6112356 | |
| facebook.com/Orgenesis-Inc-101879208270597 | |
| YouTube | youtube.com/channel/UCMyvWvSUuJt0Hvmis-EIrhg |
Identifiers & details
| Legal name | Orgenesis Inc. |
|---|---|
| Founded | 2008-6 |
| Employees (exact) | 77 |
| Offices | Germantown |
| Market cap | $776K |
| Status reason | Public on NASDAQ on Mar, 2018; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2011-08 | NASDAQ | ORGS | |
| Underwritten Public Offering | 2023-10 | NASDAQ | ORGS |
Radar intelligence
Patents
| EPO | 33 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514678937 |
|---|---|
| Status | פעילה/בפירוק - הליך פשרה או הסדר/פירוק זמני |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2011-10-11 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | פנחס ספיר 8 נס ציונה |